HC Wainwright Increases Earnings Estimates for CorMedix

CorMedix Inc (NASDAQ:CRMD) – Investment analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of CorMedix in a note issued to investors on Friday, August 14th. HC Wainwright analyst B. Folkes now expects that the company will earn $0.54 per share for the year, up from their prior forecast of $0.51. The consensus estimate for CorMedix’s current full-year earnings is $0.54 per share. HC Wainwright also issued estimates for CorMedix’s FY2029 earnings at $1.23 EPS and FY2030 earnings at $1.71 EPS.

CorMedix (NASDAQ:CRMD) last posted its earnings results on Thursday, August 13th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.24 by $0.05. The firm had revenue of $101.93 million for the quarter, compared to analysts’ expectations of $96.04 million. CorMedix had a return on equity of 40.52% and a net margin of 40.49%.

CRMD has been the topic of a number of other reports. Leerink Partners raised their price target on CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, April 28th. Citizens Jmp reiterated a “market outperform” rating and issued a $19.00 target price on shares of CorMedix in a research report on Tuesday, April 28th. Needham & Company LLC raised their target price on shares of CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Weiss Ratings reissued a “hold (c)” rating on shares of CorMedix in a research note on Tuesday, August 11th. Finally, Royal Bank Of Canada boosted their price target on shares of CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

CorMedix Trading Up 1.7%

Shares of CRMD stock opened at $7.67 on Monday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.36 and a current ratio of 2.56. CorMedix has a 1 year low of $6.13 and a 1 year high of $14.96. The stock has a fifty day moving average of $8.12 and a two-hundred day moving average of $7.64. The firm has a market capitalization of $597.80 million, a PE ratio of 3.58 and a beta of 1.50.

Institutional Trading of CorMedix

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRMD. Russell Investments Group Ltd. boosted its holdings in CorMedix by 22.2% during the second quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company’s stock worth $81,000 after buying an additional 1,190 shares in the last quarter. Gryphon Financial Partners LLC increased its holdings in shares of CorMedix by 6.3% in the first quarter. Gryphon Financial Partners LLC now owns 27,401 shares of the company’s stock valued at $186,000 after buying an additional 1,618 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of CorMedix by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,987 shares of the company’s stock valued at $222,000 after buying an additional 1,631 shares in the last quarter. Financial Management Professionals Inc. acquired a new stake in shares of CorMedix during the 4th quarter valued at $25,000. Finally, Comerica Bank lifted its position in shares of CorMedix by 454.6% during the 3rd quarter. Comerica Bank now owns 2,690 shares of the company’s stock valued at $31,000 after acquiring an additional 2,205 shares during the last quarter. 34.18% of the stock is owned by institutional investors and hedge funds.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.